Bone Marrow Cells in Myocardial Infarction

University of Oulu100 enrolled

Overview

This study is aimed to assess the effect of bone marrow cells on arrhythmia risk variables in patients with a acute myocardial infarction.

This is a randomized, double-blinded study, where patients treated with thrombolytic therapy for acute myocardial infarction are randomized to receive bone-marrow derived stem cells or sham-infusion at the time percutaneous coronary intervention of the target vessel. The end-points are many arrhythmia risk variables, suchs as heart rate variability, T-wave alternans and many ECG variables as well as systolic and diastolic left ventricular function.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

100

Conditions

Acute Myocardial Infarction

Interventions

intracoronary injection of bone marrow cellsPROCEDURE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Acute ST-elevation myocardial infarction treated with thrombolytic therapy Exclusion Criteria: * Indication for rescue PCI, severe clinical heart failure, age \<18 years

Locations (1)

University of Oulu

Oulu, Finland

Outcomes

Primary Outcomes

Arrhythmia risk variables

left ventricular function

restenosis assessed by IVUS

Secondary Outcomes

exercise tolerance

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.